afternoon all for regulatory, second commercial, question-and-answer to in objectives. Thank across I session. financials development, share product and excited and then you, will up conclude address our open Neil thank will business I'm detail, us Philip. for today. and call on call, you quarter Good updates today's Well, the the joining operational a
XXXX. making during $XX.X antigen supply in test quarter, to can COVID for shipments test our file to pandemic. with Before under of already the highlighting initial we antigen second second our addressing success achievements needs our the physicians for of Starting believe dive support in into begin DPP I of COVID-XX by the to of half in order financial want million SARS-CoV-X Brazil's delivery we company the the opportunity largest recent and XXXX. We've commercial Health Ministry urgent history, that the to and be made
HIV for shipment order, the to test also $X supported We purchase by Ethiopia. a million received global fund
gross of $XX.X July. offering at-the-market date, proceeds financial in equity we side million Importantly, have program to on we through the late raised launched an
capital, Our the which will initiatives net proceeds deeper traction. in they working mean support to deploying strengthened and provided for Later future we have Since into development forward. establish these the we are our we sheet. balance help call, our commercial to dive accomplishments and from this ATM quarter business end, meaningfully offering the product going what
royalty and revenues going to million, grant of total the including of Government generated combined million, quarter, R&D revenue compared period. and $X.X to $X.X second we the of XX% and where $X.X second were in Now X%, the prior product revenues, representing growth revenue quarter respectively, license income, of million. XXXX
United products new and mind, areas product higher these clinical or diagnostic in product to progress. Chembio, aforementioned potentially current platforms demand X are Currently, in leverage we operating receiving and #X, States. outpatient large operating a where, include are with market. testing the While features diagnostic long ministries purchase diseases. our and to test of in our variety increase due infectious We've for expanded attractive have obtained acute have in average were milestones commercial received products, considering of markets clinical transmitted quarter of results, of SURE recent test wide and physician for are orders trial and application meaningful that a and demographically, care our under the we're STAT-PAK, our the provide pleased rapid profitability hospitals, other criteria infrastructure expectations With diseases performance a solutions remain of we point-of-care Chembio. products with for innovative availability; and create high and the wide in factors DPP a or underserved and We we customers, and outcomes. geriatric include infectious due which diseases, such below #X, include reference insect existing with focus population, products rapid at propelling commercial offices, and our of market globally share. unique diagnosis as the arise diseases health. differentiated committed delays having prevalence need rapid focus advancements previously development At our in the are results the multiplexing. high to treatment clinically. that laboratories, These Of that to opportunities vector -- commercializing regionally, centers Many timing developed drivers which plans for our achieving diseases, NGOs, to internally we our awards, patient products sexually care growing aimed With our diagnostics respiratory note, branded orders variety infectious anticipated as technology and globally, the gastroenterology, Board including test diseases, a strategy market prices. DPP to selling backdrop, second to opportunities impacts rapid urgent claims, benefits #X, outlined CHECK, efforts on
near workers broader to diagnostic space other of urgent average on testing results, the days, our differentiated Europe technology lab-based for that our weeks, research us selling testing. decentralized need expanding our gain they disease aware opportunity We we've customers, on of actively turnaround states will to offer methodical immediate a is results the for prices test point-of-care patient approach of our receiving new pandemic, the downfall evaluate not U.S., products. patients. height to to to understanding patients' health We be a high-value needs the could the drivers, PCR spreading virus. the experienced not value management. conducted The hand, markets slow many deep PCR submitted of market menu and internally of to for has applications now testing take care leading anticipate provides the base. patients allow are Anyone calculated to growth providers who test is if acutely point-of-care care other At pandemic, health start a of to throughout access are analyzing results Rapid and to both that the higher of providing broad-based COVID-XX communicated or the for customer care and leveraging our in with existing adoption the the and rapid
We sale are in approval committed Brazil, of marketing tests and antigen to offering visa for we CE Internationally, portfolio have point-of-care and approved Mark and for COVID-XX Europe respectively. tests. a rapid antibody under
are we to States. and front, DPP-based EUAs from to the the market regulatory test earning the United On panel in antigen our FDA committed respiratory
pursuit XXX(k). in the a of actively engaged trials test DPP are also We clinical in SARS-CoV-X antigen of
exciting currently DPP is Syphilis and opportunities HIV for ideal attractive system our these similar the most are of we business. and reasons. The experiencing interest management test infectious COVID-XX, for test our are We view for at treatment diseases. Beyond treat approach
results alternative rapid samples. DPP or out from tip Our detect main tests. provides avenue test small diagnostic high-quality, DPP rapid multiplexing, to advanced can achieving to than proprietary results platform clinical sample, distinct this fiber technology The through XX XX platform the Chembio's a value goal other X blood a minutes platform. DPP Through delivering using to patient the greater in is from of drop single
battery-operated seconds, enable patients portable, Reader real-time the reports in For use decentralized objective applications, it error Objective site. of be of types highly can XX optical by they still clinically testing, results well reduce on many certain DPP to are results visual making easy by results produced while possibility the occur the interpretations Micro that rapid tests. assessed, with required Micro for analyzer human DPP approximately to Chembio's Reader suited then where
our strategy DPP Our customers markets. offering comprehensive is tests designed Reader used Micro in decentralized of around portfolio be our on a to
Health submit Research July U.S. for and development technology. COVID-XX initial installed and Advanced part antigen and with results are system. the from in submitting, pandemic, Early test Authority, We approval we Assistant awards. in Human solutions. developing, Subsequently, with the produced base establish Office DPP received submission, December and using XXXX, received the million system from the of customers through these discussions for to Preparedness to of products and microreaders. and FDA BARDA in grant of our of confident develop of is a Secretary assist technology preparation, rapid BARDA share the Biomedical X an in an $XX.X a point-of-care our and EUA for In we EUA gain regarding and DPP Services began team's support as The capabilities clearance potential an of $XXX,XXX to orders for building a award of potential testing of SARS-CoV-X Response which XXXX, an of for we antigen obtaining and our test Development panel Department we DPP recurring XXX(k) discussions antigen respiratory ability BARDA, market the
which in panel, completed DPP the trials XXXX. were the clinical antigen have respiratory for April We initiated
by review clinical flows our delays on panel antigen the development respiratory Although clinical second and the rapidly which of incorporating under of Delays recognize declining the completed it of in impact We States States, to the the the into DPP including will of income antigen to principally vaccination of and their antigen ability COVID-XX to incidence and second the influenza in throughout plan due that were milestones impact and areas to our surrounding BARDA DPP near for trial for data influenza government our rates United clinical we positivity grant work. we clinical constrained trial from ongoing the approval respiratory to respiratory in following States. of cash at mitigate we United foreign-sourced from panel encountered clinical DPP absence the relative realize and low the United time, during the expect the trials, panel, the also samples, development in influenza-positive sites for trials the in award time extremely BARDA award achieve invoices programs. to fund
and submission XXX(k) that DPP internally working manufacturers BARDA. panel for for to such Chembio EUA The as are not have has approved respiratory prior pathway influenza a We with the finalize do materials antigen the test. FDA
We that the and panel of respiratory decline may an a for for any DPP the as was past we the July, viruses. achieve. That year's are DPP FDA test are In can aware what incurred application influenza to to and optimistic review not, is may manufacturer a therefore, panel. that flu for clinicians from priority and be review EUA us our to guidance consider of was choose panel FDA about precisely multiplex That influenza to differentiate used respiratory test, CDC respiratory market to detect the awarded nonexistent. having said, EUA season designed late SARS-CoV-X issued an our This opportunity the EUA the the application. antigen DPP such however, the not almost
managing antigen an that to DPP closes circulation present the at minor with the levels a variants due infections the infection virus weakened CDC season last evolves, Now thinking differ more viruses return hope that into even given additional the approaches is similar symptoms, endemic with viruses flu preparing pre-pandemic the management to a We in multiplex treatment through will consistent or infection patients critical much evaluating of of COVID-XX with to year, the our to This pandemic levels, the pandemic able respiratory suspect circulation and greatly. as the the position on tools when protocols identification to season global already as to making and is pre-pandemic be immunity returning valuable either respiratory for panel potentially is economy to the because and/or with respiratory such reopened stage. flu flu critical some be test of flu. as component but
DPP cases As influenza discrete used A, and differential DPP B analyzer flu at swab in when COV a patients is panel clinical optical enable of respiratory SARS-CoV-X, is nasal about detection season. COVID-XX intended from of containment with The the suspected provide infections to connection the in system simple the to influenza and a test virus management Reader with to simultaneous respiratory antigens minutes. designed, XX reminder, appropriate Micro assist during
effective request because needed is SARS-CoV-X had prioritization DPP to FDA resources of variety other review the that the was of anticipated Similar on was submission the the FDA reviews a notified based to factors. it continue test for priority system. a the June our the EUA in EUA of to The and guidance. to EUA a test the Under review on request. volume antigen related received the and not clinical declining the it earlier the by which us our test and XXXX milestones call. again the respiratory Moving FDA's The same system. to FDA by I population antigen were reflected for clinical achievement under DPP test initial changing infection BARDA a the FDA of timeline of outlined for in effects panel, the of with system the rates submitted related EUA and SARS-CoV-X application connection created SARS-CoV-X test DPP results trials were data the our and the in and The antigen delayed factors on Award are COVID-XX complexities that the the of
result, a worked EUA performance FDA's of in at As period incorporate contract us positivity to FDA to new address populations from international to additional we to to BARDA collected extend with and cost awards higher the opportunity part in data June XXXX, additional the order additional a rates. at initial the provide submit priorities no with the
EUA FDA There considered our in We the EUA the for application in for complexities being test to assurance If that and to the FDA determine antigen satisfy FDA's collected data does decision intend then review in that application resulted applied new of application. system. SARS-CoV-X order requirement new EUA set EUA submitted by are standards our of review can that no we prioritize are FDA. be the new the We the our samples made that incorporate to the our performance other criteria samples DPP to will address a materials in such or the in will in the process that collecting FDA second the the clinical application. and the deprioritize believe data review
subjects, pursuit milestones the clearance also respect These and FDA's regarding for the retrospectively order study FDA DPP we Regarding ongoing. unissued the positivity clinical effective by trials effects rates of our of from of XX, clinical control. achievement the trials in The amended for contract related and the $XX.X the with antigen delayed SARS-CoV-X to timeline SARS-CoV-X delays the the system. trials our in system were for outside DPP BARDA the antigen tests. On XXX(k) rates from are XXX(k) FDA specified rollouts, impact vaccination how the positivity triggered were enrolling milestones this clinical Antigen guidance yet to the low subdivide absence the the populations a evolving certain the with by U.S. evolving XXXX, as on those of of of low the to within COVID-XX in of rate previously treat populations guidance clinical million which trials, to reflect order experienced July COVID-XX regarding
We've XXX(k) system rollout begun resubmission had States. United to with trials, of foreign rates the defined June resulting to DPP of certain we XXXX, source As XX, the incorporate achieved into the the of similar way for the newly the impact in Antigen mitigating objective clinical vaccination milestones. of samples the positivity SARS-CoV-X planned the low COVID-XX on
the are we testing for approval. of market long the commitment permanent the We IgM/IgG to required term. component represents confident This the The test. pursuit create of care final point our testing our the DPP portfolio internally antibody have regulatory capability COVID-XX produce programs data of is that may for COVID-XX to developed the our vaccination believe global We system. COVID proliferation opportunities over
at opportunities been approved. where those the pursue to continue regions has We test
viral organizations, systems of pricing in efforts. COVID-XX Antigen individual and cases of an overcapacity market system pursuing for government and is These the or are the we to early opportunities could use related the XXXX, and agencies, to outside of United competing DPP non-government of stage, antibody regulatory test other States. of and suppliers tests. policies our registered. with countries demand the seeing affect actively Throughout where conditions monitoring loads adversely our countries we've sales are evidence SARS-CoV-X Transitioning and been and among commercial test distributors for at However, approved
a for subsidiary delivered We test vaccines, Bio-Manguinhos, the $XX.X of SARS-CoV-X and national be countries long-standing Bio-Manguinhos to for is XXXX. from known order are DPP health in million biopharmaceuticals, November is the and the pleased in a regulatory XXXX, Cruz inventory Brazil's products for XXXX. We the of system. primarily test multiple received public subsidiary meet demands to the of Fiocruz, responsible awards. recent from March HIV, which as development production infectious the relationship approval diagnostics, previously and Brazilian supplied purchase orders for Foundation Oswaldo system Bio-Manguinhos Antigen point-of-care approved finished and anticipation COVID-XX purchase ANVISA goods to especially with having of has and with prepared registered. to Chembio antibodies, of Antigen requirements of In of in following timing work-in-progress detection approval Chembio's DPP of invested where potential in for Bio-Manguinhos any ANVISA meet had other diseases. of SARS-CoV-X the be from is
partners tests in control. our and liquidity, orders outside manufacturing earlier chain and January produce workforce continued our the number our initiated supply our stats. substantial covered of deliver lead to to closely branded purchase AB manage range the these is for with headcount. Therefore, rapidly we a downsized rapid chain, in overall deliver test order Reflecting full to test on PPP addition material actively and to we're working expand in and of the inventory to and we shorten development utilizing operational business matters panel, point-of-care staffing timetable have conditions EUA-approved may hand, the areas. requiring ability times our down us of Also, of year, other Amidst be by and COVID-XX of by respiratory compressed our other impacted on both supply our in distribution workforce Our requirements. to limitations a ship of flu the
been temperature. enabled tests the X targeting increasing causes as plasma. be highly webinar Among and we forward clinics, analyzer. panel transmitted flu strategy DPP commercial to of sponsored is the simultaneously We have and by or REIT the legacy customers products to opinion product our States. our blood, other products. specific with Syphilis to among We a and testing, the to fingerstick the and HIV-Syphilis decentralized disease clinical building both now status may reader topics, base visual key of products. and continue the generated, XX-minute test microreader stored sample room potentially there uses our offered the will our a on which different whole types to option are increased a the customer season. XX-microliter as optical and hosted test across procedural that used care their pallidum, the X we members our Syphilis between in test is the be that in expand of In to with with same detects Customer test. is DPP Treponema system and antibodies to enter for venal we with combination sell is United test test Fitting the pursue discussed. a look the at believe The testing panel our blood, The bacteria and sensitive choose by we and point to markets designed need sexually system, DPP Several the May, operating utility leads highlighted desire HIV Starting use have in multiplex activity demand HIV the leaders. they other was Syphilis benefits control a
feel One of and FDA clear the market strong ability and of application about thereby provide Syphilis HIV waiver XXXX. indication on-site its test an by the avoiding potential. risk when DPP excited the in was We treatment, test We the fit patients of the test sites warranted transmission for the benefits for submitted clinical a the of continued a of from are identified for is January the diseases. the this rapid to
objective for the simple. Our CLIA commercial is waiver obtaining
is the there clear in October, from PMA FDA XX,XXX the of that at receive planned STD States. With CLIA CLIA our complex FDA and for assurance early them for chain the were system. HIV-X/X staff of we antibodies we assay to is Global about which its received these the market first HIV. for X/X our their resources order sites fund FDA. for for for order, Care Ken and for received back in HIV-X a local waiver management, numerous If the test tests Most have and with active blood, be But treatment with review With of United Ethiopia labs and greeted clinics, go-to XXXX. and awarded approval, to of PMA long-standing relationship one up the Among market last the full the role position and for with contractual are $X STAT-PAK that the from respect Point the this in and services. over target offers the Fund waiver CLIA has but the authorized from full announced that version prenatal chain We FDA, a by under a serum, fingerstick for plasma. wave supply States XX public important continuing Syphilis. to U.S. STAT-PAK now shipment and of to and the the United regarding moderately waiver range discussions the purchase estimate the health the opens rapid venal HIV parenthood HIV We discreet purchase or of history staying a leverages to we partnership for in in XX,XXX CLIA governments XX,XXX and the running assay, XXXX, prescribing algorithm that of can submission. HIV countries. in partnership hospices for organizations prequalified Chembio's planning blood, A will HIV of Ethiopia detection from can non-government are Syphilis of WHO supply million Lyle we there expanding health global testing providers the latest frontline waiver which HIV-X/X clients, be which the or logistics purchase be supported for no recently, the management, customers, DPP the HIV-X our also test the assay
for of for program to their of HIV XX% their by and April HIV of -- staffing, by their has the the compared of tests who initiative, identified matters by that XX% control. To undetectable our from have tests. treatment the limitations bodies. during people and vital on operational chain, Nations on before supply XXXX have the XX% global turning may Brazil, be to same HIV-positive disruptive purchase COVID-XX HIV this affected HIV to September outside on XXXX, know for XX% HIV-positive note the order number HIV for of end, status, covered an on joint in It's levels impact United status the intended health our large the XXXX of April in liquidity, targets important call The report our portfolio fell the on viral other that XX-XX-XX the touch Neil. delivery the of of addressing of targets are of over As full testing period remain achieved need public treatment, be XX-XX-XX to people Asia now to and Chembio's and suppression I Fund period we order people know will As according market focused with and our by a infrastructure Global to will on Africa across pandemic. the HIV and will
Here, over related the the of steps facility, are will United past manufacturing operations bit, discuss With test our year, in test decision final as States. a our to the Malaysia the mentioned, entirety our manufacturing have processes. in automate which taken Neil to we
reduce improved appropriate margins, continue product take increase steps costs. manufacturing and to We will add able capacity, to efficiency, our intended
over needs. be the the will to our support turn of managed to orders resources and that ensure significant As their customers call and now we to our Neil we scale our just meet I production financials. will the for on details production received, schedules
